PURPOSE: The clinical significance of bilateral breast cancer is unclear and its influence on prognosis is controversial. We compared the characteristics and prognosis of bilateral breast cancer and unilateral breast cancer. METHODS: Our study included 4,183 patients with breast cancer who were treated at Sun Yat-sen University Cancer Center between January 1, 2000, and December 31, 2007. Bilateral breast cancer was categorized as synchronous (within 3 months) or metachronous (diagnosed after 3 months of first cancer). SPSS was used for data analysis. RESULTS: 106 (2.5%) and 31 (0.7%) patients were diagnosed with metachronous and synchronous bilateral cancer. Women with bilateral cancer had more frequent postmenopause, HER-2 negativity, and advanced disease than in patients with unilateral cancer. Young age at diagnosis, invasive lobular carcinoma, ER/PR negativity, HER-2 positivity, radiation, large tumor size (T > 5 cm), and stage III disease of the first cancer were risk factors for contralateral cancer. The 5-year disease-free survival and overall survival rates were 76 and 83% for unilateral cancer, while 32 and 72% for bilateral cancer (P = 0.000 for both). CONCLUSIONS: Bilateral cancer was associated with shorter disease-free survival and overall survival than unilateral cancer. The prognosis of metachronous bilateral cancer, especially those diagnosed within 2 years after the first cancer was significantly worse than synchronous bilateral cancer.
PURPOSE: The clinical significance of bilateral breast cancer is unclear and its influence on prognosis is controversial. We compared the characteristics and prognosis of bilateral breast cancer and unilateral breast cancer. METHODS: Our study included 4,183 patients with breast cancer who were treated at Sun Yat-sen University Cancer Center between January 1, 2000, and December 31, 2007. Bilateral breast cancer was categorized as synchronous (within 3 months) or metachronous (diagnosed after 3 months of first cancer). SPSS was used for data analysis. RESULTS: 106 (2.5%) and 31 (0.7%) patients were diagnosed with metachronous and synchronous bilateral cancer. Women with bilateral cancer had more frequent postmenopause, HER-2 negativity, and advanced disease than in patients with unilateral cancer. Young age at diagnosis, invasive lobular carcinoma, ER/PR negativity, HER-2 positivity, radiation, large tumor size (T > 5 cm), and stage III disease of the first cancer were risk factors for contralateral cancer. The 5-year disease-free survival and overall survival rates were 76 and 83% for unilateral cancer, while 32 and 72% for bilateral cancer (P = 0.000 for both). CONCLUSIONS:Bilateral cancer was associated with shorter disease-free survival and overall survival than unilateral cancer. The prognosis of metachronous bilateral cancer, especially those diagnosed within 2 years after the first cancer was significantly worse than synchronous bilateral cancer.
Authors: Alan M Nichol; Rinat Yerushalmi; Scott Tyldesley; Mary Lesperance; Chris D Bajdik; Caroline Speers; Karen A Gelmon; Ivo A Olivotto Journal: J Clin Oncol Date: 2011-11-21 Impact factor: 44.544
Authors: Mikael Hartman; Kamila Czene; Marie Reilly; Jonas Bergh; Pagona Lagiou; Dimitrios Trichopoulos; Hans-Olov Adami; Per Hall Journal: Lancet Oncol Date: 2005-06 Impact factor: 41.316
Authors: Helena M Verkooijen; Vanessa Chatelain; Gérald Fioretta; Georges Vlastos; Elisabetta Rapiti; André-Pascal Sappino; Christine Bouchardy; Pierre O Chappuis Journal: Breast Cancer Res Treat Date: 2006-12-21 Impact factor: 4.872
Authors: L A Newman; A A Sahin; J E Cunningham; M L Bondy; N Q Mirza; G S Vlastos; G J Whitman; H Brown; T A Buchholz; M H Lee; S E Singletary Journal: Cancer Date: 2001-05-15 Impact factor: 6.860
Authors: Marilyn Stovall; Susan A Smith; Bryan M Langholz; John D Boice; Roy E Shore; Michael Andersson; Thomas A Buchholz; Marinela Capanu; Leslie Bernstein; Charles F Lynch; Kathleen E Malone; Hoda Anton-Culver; Robert W Haile; Barry S Rosenstein; Anne S Reiner; Duncan C Thomas; Jonine L Bernstein Journal: Int J Radiat Oncol Biol Phys Date: 2008-06-14 Impact factor: 7.038
Authors: Colin B Begg; Irina Ostrovnaya; Felipe C Geyer; Anastasios D Papanastasiou; Charlotte K Y Ng; Rita A Sakr; Jonine L Bernstein; Kathleen A Burke; Tari A King; Salvatore Piscuoglio; Audrey Mauguen; Irene Orlow; Britta Weigelt; Venkatraman E Seshan; Monica Morrow; Jorge S Reis-Filho Journal: Int J Cancer Date: 2017-09-28 Impact factor: 7.396
Authors: Elżbieta Senkus; Jolanta Szade; Beata Pieczyńska; Anna Zaczek; Joanna Pikiel; Katarzyna Sosińska-Mielcarek; Agnieszka Karpińska; Jacek Jassem Journal: Int J Clin Exp Pathol Date: 2013-12-15
Authors: Hüseyin Kadioğlu; Serdar Özbaş; Alper Akcan; Aykut Soyder; Lutfi Soylu; Savaş Koçak; N Zafer Cantürk; Mustafa Tükenmez; Mahmut Müslümanoğlu Journal: World J Surg Oncol Date: 2014-08-20 Impact factor: 2.754